Limits...
Integration of host strain bioengineering and bioprocess development using ultra-scale down studies to select the optimum combination: an antibody fragment primary recovery case study.

Aucamp JP, Davies R, Hallet D, Weiss A, Titchener-Hooker NJ - Biotechnol. Bioeng. (2014)

Bottom Line: The ability of cells to resist breakage was dependant on a combination of factors including host strain, vector, and fermentation strategy.The use of scale-down primary recovery process sequences can be used to screen a larger number of engineered strains.This can lead to closer integration with and better feedback between strain development, fermentation development, and primary recovery studies.

View Article: PubMed Central - PubMed

Affiliation: Bioprocess Research and Development, Novartis Phama AG, Basel, Switzerland. jean.aucamp@novartis.com.

Show MeSH

Related in: MedlinePlus

Schematic representations of the USD devices. A: The rotating disc subjects test material housed in the chamber to shear treatment. B: The capillary discharge device accelerates test material housed in a syringe chamber through a capillary onto an impaction disc.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4282095&req=5

fig01: Schematic representations of the USD devices. A: The rotating disc subjects test material housed in the chamber to shear treatment. B: The capillary discharge device accelerates test material housed in a syringe chamber through a capillary onto an impaction disc.

Mentions: USD feed zone studies were conducted with a rotating disc device (RDD) depicted in Figure 1A (Boychyn et al., 2001). Fermentation broth was loaded into the 4°C pre-chilled chamber of the RDD and the disc rotated at preset speeds for 20 s. Shear treatment was performed at nine rotation speeds in the range of 4,000–21,000 rpm corresponding to 1.7 × 103–8.2 × 103 s−1 maximum shear rates. Samples were centrifuged at 13,000 rpm for 5 min in a Hettich Mikro 200 microfuge (Tuttlingen, Germany) and the supernatant retained for analysis.


Integration of host strain bioengineering and bioprocess development using ultra-scale down studies to select the optimum combination: an antibody fragment primary recovery case study.

Aucamp JP, Davies R, Hallet D, Weiss A, Titchener-Hooker NJ - Biotechnol. Bioeng. (2014)

Schematic representations of the USD devices. A: The rotating disc subjects test material housed in the chamber to shear treatment. B: The capillary discharge device accelerates test material housed in a syringe chamber through a capillary onto an impaction disc.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4282095&req=5

fig01: Schematic representations of the USD devices. A: The rotating disc subjects test material housed in the chamber to shear treatment. B: The capillary discharge device accelerates test material housed in a syringe chamber through a capillary onto an impaction disc.
Mentions: USD feed zone studies were conducted with a rotating disc device (RDD) depicted in Figure 1A (Boychyn et al., 2001). Fermentation broth was loaded into the 4°C pre-chilled chamber of the RDD and the disc rotated at preset speeds for 20 s. Shear treatment was performed at nine rotation speeds in the range of 4,000–21,000 rpm corresponding to 1.7 × 103–8.2 × 103 s−1 maximum shear rates. Samples were centrifuged at 13,000 rpm for 5 min in a Hettich Mikro 200 microfuge (Tuttlingen, Germany) and the supernatant retained for analysis.

Bottom Line: The ability of cells to resist breakage was dependant on a combination of factors including host strain, vector, and fermentation strategy.The use of scale-down primary recovery process sequences can be used to screen a larger number of engineered strains.This can lead to closer integration with and better feedback between strain development, fermentation development, and primary recovery studies.

View Article: PubMed Central - PubMed

Affiliation: Bioprocess Research and Development, Novartis Phama AG, Basel, Switzerland. jean.aucamp@novartis.com.

Show MeSH
Related in: MedlinePlus